St. Louis researchers receive recognition for groundbreaking Alzheimer’s diagnostic test
When the diagnostic test PrecivityAD hit the market in 2020, it democratized early detection of Alzheimer’s disease. The blood test, developed by C2N Diagnostics, is more accessible than brain imaging and spinal fluid tests, which can be expensive and invasive. WashU Medicine professor and C2N Diagnostics co-founder Dr. David Holtzman talks about his team’s innovation and how their work has contributed to our understanding of the disorder and how to treat it. He also shares how the commercialization process afforded to universities through the Bayh-Dole Act of 1980 has brought innovative discoveries like PrecivityAD to the general public. Holtzman and his colleague, Dr. Randall Bateman, will receive the American Innovator Award from the Bayh-Dole Coalition in Washington, D.C. next week.
You May Also Like

ABC News Top Stories
ABC Australia

Asmongold TV
Asmongold TV

Las noticias de la SER
SER Podcast

DS Vandaag
De Standaard

Entertainment Tonight
CBS Media Ventures
Clark County Today News
ClarkCountyToday.com

ABC News Update
ABC News

The Great America Show
Fawcett Strategies

AP Newswatch: Top Stories from the Associated Press
The Associated Press

Jeffrey Epstein: The Coverup Chronicles
Bobby Capucci
Community discussion